Displaying drugs 15501 - 15525 of 16351 in total
Bomtabegagene bavoparvovec
Investigational
Verbrinacogene setparvovec
Investigational
Engabexagene cincesparvovec
Experimental
NeuroVax
Investigational
AGIL-FA
Investigational
Latozinemab
Investigational
BLS-M22
Investigational
PR006
PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene. It is being investigated for the treatment of dementia.
Investigational
BMN-044
Experimental
Withdrawn
BMN-046
Experimental
Withdrawn
Alirinetide
Investigational
BMN-055
Experimental
Withdrawn
GliSODin
Investigational
Nutraceutical
MTI-201
Investigational
GTA002
Investigational
CE-VST01-JC
Investigational
OS2966
OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]
Investigational
Matched Description: … CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and …
DP-303c
Investigational
Murlentamab
Investigational
Lerapolturev
Investigational
ALT-P7
Investigational
ST-36
ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.
Investigational
SNS01-T
SNS01-T is a gene therapy nanoparticle. It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.
Investigational
Matched Description: … eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and …
Displaying drugs 15501 - 15525 of 16351 in total